trial

A Study of Staccato Loxapine (ADASUVE®) for Inhalation

NCTId NCT04148963
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 150 (estimated)
Sponsored by Lee's Pharmaceutical Limited
Primary completion 2020-05-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-12-01
Primary completion
2020-05-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Inhaled loxapine

Sponsors

Lee's Pharmaceutical LimitedLead Sponsor

Sites

0 total

Linked catalysts

1
A Study of Staccato Loxapine (ADASUVE®) for Inhalation — primary completion2020-05-01

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE3
Primary Completion Date
2020-05-01
Status
UNKNOWN
relationships
The graph out of here
drug
Inhaled loxapine
drug
lead_sponsor
Lee's Pharmaceutical Limited
company
indication
Bipolar Disorder
indication
Psychomotor Agitation
indication
Schizophrenia
indication